To find how prevalent problems are in regulatory filings to start clinical trials and for product approvals in China, one doesn’t have to read far within China’s annual report on new drug reviews, released on 21 June by the National Medical Products Administration (NMPA), to find out.
In 2020, the regulatory agency approved 20 innovative new products, including 14 drugs, four traditional Chinese medicines and two biologics. There were 72 approvals for imported drugs, including additional indications....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?